CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-10-30 | Ege David S. | Sale 10b5-1 | −4,066 | $1.35 | $5K | 66,991 |
| 2023-10-30 | von Moltke Lisa | Sale 10b5-1 | −4,232 | $1.35 | $6K | 9,513 |
| 2023-10-30 | Henn Matthew R. | Sale 10b5-1 | −3,886 | $1.35 | $5K | 56,356 |
| 2023-10-27 | Cloghessy Paula | Exercise or conversion 10b5-1 | +9,418 | 48,588 | ||
| 2023-10-27 | Cloghessy Paula | Exercise or conversion · Restricted Stock Units 10b5-1 | −9,418 | 9,417 | ||
| 2023-10-27 | Shaff Eric D. CEO and President | Exercise or conversion 10b5-1 | +27,838 | 124,172 | ||
| 2023-10-27 | Shaff Eric D. CEO and President | Exercise or conversion · Restricted Stock Units 10b5-1 | −27,838 | 27,837 | ||
| 2023-10-27 | Young Teresa L. | Exercise or conversion 10b5-1 | +11,361 | 11,361 | ||
| 2023-10-27 | Young Teresa L. | Exercise or conversion · Restricted Stock Units 10b5-1 | −11,361 | 11,360 | ||
| 2023-10-27 | Arkowitz David Chief Financial Officer | Exercise or conversion 10b5-1 | +13,209 | 179,822 | ||
| 2023-10-27 | Arkowitz David Chief Financial Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −13,209 | 13,209 | ||
| 2023-10-27 | DesRosier Thomas Chief Legal Officer and EVP | Exercise or conversion 10b5-1 | +13,501 | 118,047 | ||
| 2023-10-27 | DesRosier Thomas Chief Legal Officer and EVP | Exercise or conversion · Restricted Stock Units 10b5-1 | −13,501 | 13,500 | ||
| 2023-10-27 | Ege David S. | Exercise or conversion 10b5-1 | +11,361 | 71,057 | ||
| 2023-10-27 | Ege David S. | Exercise or conversion · Restricted Stock Units 10b5-1 | −11,361 | 11,360 | ||
| 2023-10-27 | von Moltke Lisa | Exercise or conversion 10b5-1 | +13,745 | 13,745 | ||
| 2023-10-27 | von Moltke Lisa | Exercise or conversion · Restricted Stock Units 10b5-1 | −13,745 | 13,744 | ||
| 2023-10-27 | Henn Matthew R. | Exercise or conversion 10b5-1 | +12,623 | 60,242 | ||
| 2023-10-27 | Henn Matthew R. | Exercise or conversion · Restricted Stock Units 10b5-1 | −12,623 | 12,622 | ||
| 2023-06-22 | Biondi Paul Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 |
Page 17 of 23 · 458 trades